AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06598722
Drug: BCL-2 inhibitors combined with the HyperCVAD regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCL-2 inhibitors combined with the HyperCVAD regimen for newly diagnosed adult T-ALL/LBL
Trial: NCT06605495
Drug: Modern Western Medicine
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referring to the Chinese Expert Consensus on Dry Eye: Treatment (2020), this course of treatment totaled 6 weeks.
Trial: NCT05244551
Drug: ABSK061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the escalation part, patients will receive a single dose of oral ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in subsequent cycles (28-day cycles). The starting dose is 5 mg BID. In the expansion part, patients will each receive oral ABSK061 at the RDE in repeated 28-day cycles.
Trial: NCT06615596
Drug: Anticoagulant drugs
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the continuation arm will receive oral anticoagulant drugs such as dabigatran, rivaroxaban, apixaban, warfarin, etc. tailored to their specific risk profiles. The discontinuation arm will cease anticoagulation therapy following randomization. Smart wearable devices will monitor for AF recurrence, and patients will be followed for 24 months, with primary endpoints including thromboembolic and bleeding events.
Trial: NCT06632262
Drug: ABSK061 + ABSK043
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of ABSK061 + ABSK043 oral capsule until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
Trial: NCT05932459
Drug: Deuremidevir Hydrobromide for Suspension 100mg
RxNorm normalized name: hydrobromic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it with 240ml water in fasted condition.
Trial: NCT05932459
Drug: Deuremidevir Hydrobromide for Suspension 300mg
RxNorm normalized name: hydrobromic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it with water in fasted condition or after taking infant formula.
Trial: NCT05932459
Drug: Deuremidevir Hydrobromide for Suspension 25mg
RxNorm normalized name: hydrobromic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it with 240ml water on an empty stomach.
Trial: NCT05932459
Drug: Deuremidevir Hydrobromide tablets 100mg
RxNorm normalized name: hydrobromic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it with 240ml water in fasted condition.
Trial: NCT05317689
Drug: Sublingual Psilocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.18mg - 4.36mg sublingual psilocin with psychological support and physiological monitoring
Trial: NCT06267274
Drug: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of ophthalmic solution instill in both eyes every night at 10:00 pm (±1 hours) for 42 days (6 weeks) (± 4 days) as per the randomization schedule.
Trial: NCT05845008
Drug: Acetaminophen/Naproxen Sodium Fixed Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen/naproxen sodium fixed combination tablets, oral.
Trial: NCT06423261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation administration
Trial: NCT06137014
Drug: Fortified Oral Rehydration Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution with reduced glucose and added amino acids.
Trial: NCT03939104
Drug: Artemether-lumefantrine+placebo
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets.
Trial: NCT05624320
Drug: AGN-190584
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: miotic for treatment of presbyopia
Trial: NCT05099666
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage per protocol, IV per institutional standards of practice and the FDA package insert, schedule per protocol
Trial: NCT06180057
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules were administered orally
Trial: NCT05383378
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection in the abdomen
Trial: NCT06083129
Drug: Grafalon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/Kg/day IV for 3 consecutive days (day-3 to -1 before transplantation)
Trial: NCT06249867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the first two weeks (titration period), patients in the placebo arm will receive a daily dose of 1 placebo tablet. After the titration period, the dose will be increased to two placebo tablets taken together, for a period of 22 weeks.
Trial: NCT00005015
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05784051
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medical treatment including drug administration ± catheter ablation (Ablation can be performed if the PVC burden remain \>10% after 2 lines of AAD treatment).
Trial: NCT05784051
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients of this group have no therapeutic or no treatment modification such as drug therapy
Trial: NCT05446688
Drug: 6MW3211
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6MW3211 injection, 45mg/kg, Q2W
Trial: NCT05205447
Drug: LY3410738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral LY3410738
Trial: NCT05638854
Drug: ZB002
RxNorm normalized name: Zoledronic acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ZB002 will be administered subcutaneously as per schedule specified in the respective arm.
Trial: NCT05638854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously as per schedule specified in the respective arm.
Trial: NCT04864496
Drug: Prescribe placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: manufactured by Daroo Salamat Pharmed, two times daily
Trial: NCT05323201
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 i.v. for once (Day -5)
Trial: NCT04984954
Drug: MUSK pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
Trial: NCT05831930
Drug: Nituozumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nituozumab injection 200mg, administered once a week on the first day, with a duration of at least 60 minutes for a total of 7 times
Trial: NCT06056167
Drug: Degludec insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will be initiated on regular insulin sliding scale (ISS) every 6 hours, administrated subcutaneously at 0600, 1200, 1800 and 2400 in patients who are nil per os and on intravenous fluid or parenteral nutrition or continuous tube feeding, according to King Faisal Specialist Hospital \& Research Center (KFSH\&RC) protocol.~Patients with two capillary point of care glucose levels of \> 10 mmol/L (180 mg/dl) will be initiated on insulin degludec at dose of 0.2 units/ kg.~Dose adjustments will be carried out on daily basis based on blood glucose levels following a written protocol.
Trial: NCT04530864
Drug: Dextenza 0.4Mg Ophthalmic Insert
RxNorm normalized name: Dextenza 0.4mg Ophthalmic Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive pre-surgical ocular surface treatment with intracanalicular sustained release dexamethasone, 0.4 mg
Trial: NCT04525274
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of 40 ml bupivacaine 0.25% + 5 ml normal saline will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure.
Trial: NCT05722691
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once intramuscular injection (1 vial)
Trial: NCT06006689
Drug: Qishen Yiqi Dripping Pills placebo 3 bags
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qishen Yiqi Dripping Pills placebo contain Qishen Yiqi dripping pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
Trial: NCT05841160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04690283
Drug: Mimetic granules of Yiqi-Wenjing prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention relates to a multiple granules, which contains 2.5% concentrated Huangqi-Guizhi-Wuwu decoction (a classical traditional Chinese prescription consists of astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube), 2.5% concentrated Danggui-Sini decoction (a classical traditional Chinese prescription consists of angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root), bitter principle, food colouring and starch.
Trial: NCT04690283
Drug: Huangqi-Guizhi-Wuwu granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention relates to a traditional Chinese prescription granules, which contains astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube.
Trial: NCT05159908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets for oral administration
Trial: NCT06297096
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax) or methotrexate 10-25 mg/week orally or subcutaneously as above, regardless of the preparation
Trial: NCT05825092
Drug: Androgel Topical Product
RxNorm normalized name: Androgel Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AndroGel® will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. AndroGel® will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, AndroGel® will be administered in hospital wards to complete the 28 days of treatment or until hospital discharge
Trial: NCT06232096
Drug: MBS314 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase Ia: The patients confirming to the eligibility criteria will be assigned to 1 of the 7 dose groups (0.03/0.09/0.3/0.9 mg \~ 0.3/1.5/9.0/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS314 as per the schedule specified in the respective arms.~Phase Ib/Ⅱ: Based on the results of Phase Ⅰa, 1 or 2 recommended doses will be selected for Phase Ⅰb. Recommended Phase II Dose (RP2D) will be selected for Phase Ⅱ.
Trial: NCT05344729
Drug: TQB3616 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It inhibits the proliferation of tumor cells by reducing the level of retinoblastoma protein (Rb) phosphorylation in cancer cells and blocking the progression of cells from G1 to S phase.
Trial: NCT05677152
Drug: Intravenous Infusion of Aclasta®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion of Aclasta® (Verum) or physiological saline solution 0.9% (Placebo)
Trial: NCT05338463
Drug: Fespixon Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Name : Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 20 weeks
Trial: NCT05825092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. Placebo gel will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, Placebo gel will be administered in hospital wards to complete the 28 days of
Trial: NCT05167071
Drug: HBM4003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.
Trial: NCT02502370
Drug: observation alone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02502370
Drug: LV5FU2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02502370
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06222801
Drug: Tumor necrosis factor alpha
RxNorm normalized name: Tumor necrosis factor alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antitumor agent. Immunomodulatory agent.
Trial: NCT04871464
Drug: Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT06340789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the add-on placebo with conventional pharmacological treatment
Trial: NCT05791721
Drug: Etoricoxib 90 Mg Oral Tablet
RxNorm normalized name: etoricoxib 90 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention will be applied one hour before surgical extraction of impacted mandibular third molar
Trial: NCT04999098
Drug: Echinaforce Forte tablets
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~the tablet contain additional excipients
Trial: NCT04999098
Drug: Echinaforce Chewable tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~The tablets contain additional excipients
Trial: NCT04999098
Drug: Echinaforce tincture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)
Trial: NCT06475443
Drug: pyrotinib plus capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT05624294
Drug: CS0159
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT05624294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT05508516
Drug: Shugan Dingtong decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will accept Shugan Dingtong decoction 150ml (twice, per day) for 12 weeks.
Trial: NCT05072990
Drug: Chinese herb medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients took 200 ml Chinese herb decoction twice a day before breakfast and dinner.
Trial: NCT04795141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline for injection
Trial: NCT06066008
Drug: ZM-01-L
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAAV-hRS1 intravitreal injection of low dose
Trial: NCT05760053
Drug: EP/EC+PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 240 mg, administered on the first day of each cycle, and a cycle of administration every 3 weeks. Etoposide 100mg/m2, d1-3, cisplatin 25mg/m2, d1-3 or carboplatin AUC=5 d1, administered on the first day of each cycle, a cycle of administration every 3 weeks. Toripalimab combined with etoposide and cisplatin/carboplatin was used for 4 to 6 courses of treatment.
Trial: NCT04959305
Drug: HCP1803-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT04959305
Drug: RLD2003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT04959305
Drug: RLD2004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT04959305
Drug: RLD2005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT04959305
Drug: HPP2003-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug. Take it once daily for 8 weeks orally.
Trial: NCT04959305
Drug: HPP2005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug. Take it once daily for 8 weeks orally.
Trial: NCT05676073
Drug: SHEN26 dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 200mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
Trial: NCT05676073
Drug: SHEN26 dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 400mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
Trial: NCT05676073
Drug: SHEN26 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching the SHEN26 capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).
Trial: NCT04984525
Drug: SYNB1618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYNB1618 is formulated as a nonsterile solution intended for oral administration
Trial: NCT05725343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.
Trial: NCT04775030
Drug: CBD occlusal appliance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusal appliance manufactured with CBD molecules released from material to patients oral cavity during sleep time
Trial: NCT06394336
Drug: Standard treatment (oral analgesic/anti-inflammatory drug)
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral analgesic/anti-inflammatory drug. Education.
Trial: NCT06041204
Drug: Levothyroxine 25 Mcg (0.025 Mg) Oral Tablet
RxNorm normalized name: levothyroxine 25 mcg (0.025 mg) oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take letrozole at same doses as letrozole only group. Also receive levothyroxine starting at 25mcg orally once daily, titrated by 25mcg every 4 weeks to reach normal TSH, maximum 100mcg daily. Once appropriate dose determined to normalize TSH, it is maintained throughout treatment period. Compliance monitored by pill counts, TSH levels, and diary. Treatment continues for up to 6 ovulatory cycles or until pregnancy, whichever is first, maximum 6 months. Ovulation assessed by monitoring and progesterone. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Letrozole and levothyroxine taken daily at same time. All other procedures same as letrozole only group.
Trial: NCT06234397
Drug: BH3120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BH3120 will be administered as an IV infusion over 90 minutes on Day 1 of every 3-week treatment cycle
Trial: NCT06298032
Drug: Olamkicept Part B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion. Multiple doses.~Part B consists of 3 different doses.~* 1200 mg~* 1800 mg~* 2400 mg
Trial: NCT06298032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion